Browsing Tag
ISB 2001
8 posts
Glenmark’s AbbVie deal: Can ISB 2001 make it India’s first true global biologics play?
Glenmark’s AbbVie deal for trispecific antibody ISB 2001 could redefine India’s role in global biologics—find out why this partnership matters now.
Glenmark Pharmaceuticals balances modest Q1 FY26 growth with innovation drive, global partnerships and robust pipeline ambitions
Glenmark’s Q1 FY26 results reveal modest growth but highlight strong specialty launches, AbbVie licensing deal, and a robust innovation pipeline.
Glenmark Pharmaceuticals surges 10% after AbbVie licensing deal boosts ISB 2001 global reach
Glenmark Pharmaceuticals stock jumps 10% after announcing ISB 2001 licensing deal with AbbVie; find out what this could mean for its oncology ambitions.
Pharma stock watch: Are Indian midcaps like Glenmark better positioned than the giants?
Are Indian midcap pharma stocks like Glenmark set to outperform giants like Sun and Cipla? Explore 2025 trends, biotech bets, and market sentiment shifts.
Glenmark Pharmaceuticals eyes biotech leap as ISB 2001 enters global spotlight
Glenmark Pharmaceuticals’ ISB 2001 gets FDA Fast Track for multiple myeloma. Explore how this could redefine its biotech future and rival global oncology innovators.
Glenmark Pharmaceuticals posts 12.8% revenue rise in FY25, beats market estimates
Glenmark Pharma posts ₹13,894 Cr profit in FY25. Explore its global growth, R&D breakthroughs, and why ISB 2001 may define its biotech future.
Glenmark Pharmaceuticals posts strong Q3 FY2025 earnings as global expansion gains momentum
Glenmark Pharmaceuticals Limited has reported a strong financial performance for the third quarter of fiscal year 2025, driven…
Ichnos Glenmark presents data from Phase 1 study of ISB 2001 in multiple myeloma
In a presentation at the 66th American Society of Hematology Annual Meeting, Ichnos Glenmark Innovation (IGI) unveiled promising…